Skip to main content

Advertisement

SpringerLink
Log in

Letter to the editor: Is it reasonable to prescribe RAI for all DTC patients with a primary tumor diameter exceeding 1 cm?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Verburg FA, Flux G, Giovanella L, Nostrand D, Muylle K, Luster M. Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decade. Eur J Nucl Med Mol Imaging. 2020;47(1):78–83.

    Article  CAS  Google Scholar 

  2. Carhill AA, Litofsky DR, Ross DS, Jacqueline J, Cooper DS, Brierley JD, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012. J Clin Endocrinol Metab. 2015;100(9):3270–9.

    Article  CAS  Google Scholar 

  3. Ruel E, Thomas SM, Dinan MA, Perkins JM, Roman SA, Sosa JA, et al. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer [J]. J Clin Endocrinol Metab. 2015;100(4):1529–36.

    Article  CAS  Google Scholar 

  4. Zhang H, Cai Y, Zheng L, Zhang Z, Jiang N. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study. Hell J Nucl Med. 2017;20(1).

  5. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology. Thyroid Carcinoma, Version 2. 2019 (September16, 2019), https://www.nccn.org/professionals/physician_gls/

  6. Jonklaas J, Sarlis NJ, Litofsky DR, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid. 2007;16(12):1229–42.

    Article  Google Scholar 

  7. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, et al. Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid. 2010;20(12):1423–4.

    Article  Google Scholar 

Download references

Funding

The present study was supported by grants from the National Natural Science Foundation of China (grant no.81572970), Jinan Scientific and Technology Development Project (grant no.201805005), Academic Promotion Program of Shandong First Medical University (grant no. 2019LJ004), Taishan Scholars Program of Shandong Province (ts20120505), and Shandong Provincial Natural Science Foundation (grant no. ZR2019PH051).

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

    Yingjie Zhang & Xiaorong Sun

Authors
  1. Yingjie Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaorong Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaorong Sun.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

Not applicable.

Informed consent

Not applicable.

Additional information

This article is part of the Topical Collection on Letter to the Editor

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, Y., Sun, X. Letter to the editor: Is it reasonable to prescribe RAI for all DTC patients with a primary tumor diameter exceeding 1 cm?. Eur J Nucl Med Mol Imaging 47, 2505–2506 (2020). https://doi.org/10.1007/s00259-020-04858-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-020-04858-z

Search

Navigation